The Investigation of the Impact of Early Mobilization on the Outcome in Patients With Aneurysmal Subarachnoid Hemorrhage.

NCT ID: NCT06436508

Last Updated: 2024-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-14

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the randomized clinical trial is to examine the effect of early mobilization on primary and secondary outcomes in patients with subarachnoid hemorrhage caused by aneurysm rupture.

Researchers will compare early mobiliziation vs. standrad bed rest care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early Ambulation Standard of Care Subarachnoid Hemorrhage, Aneurysmal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early mobilization

This group is mobilized in the intensive care unit by the institutional physiotherapist with the assistance of specialized personnel. Mobilization is carried out according to the Early Mobilization Protocol (EMP)

Early mobilization protocol:

* Step 1 - Day 1: Bed rest, elevation of the head end to 30°
* Step 2 - Day 2: Bed rest, elevation of the head end to 60°
* Step 3 - Day 3: Bed rest, elevation of the head end to 80°
* Step 4 - Day 4: Sitting on the edge of the bed
* Step 5 - Day 5: Sitting in a chair, standing up
* Step 6 - Day 6: Walking with or without assistance
* Step 7 - Day 7: Walking with or without assistance from today

Group Type EXPERIMENTAL

Early mobilization protocol

Intervention Type BEHAVIORAL

* Step 1 - Day 1: Bed rest, elevation of the head end to 30°
* Step 2 - Day 2: Bed rest, elevation of the head end to 60°
* Step 3 - Day 3: Bed rest, elevation of the head end to 80°
* Step 4 - Day 4: Sitting on the edge of the bed
* Step 5 - Day 5: Sitting in a chair, standing up
* Step 6 - Day 6: Walking with or without assistance
* Step 7 - Day 7: Walking with or without assistance from today

Standard bed rest

No early mobilization

Group Type ACTIVE_COMPARATOR

Standard care

Intervention Type BEHAVIORAL

During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early mobilization protocol

* Step 1 - Day 1: Bed rest, elevation of the head end to 30°
* Step 2 - Day 2: Bed rest, elevation of the head end to 60°
* Step 3 - Day 3: Bed rest, elevation of the head end to 80°
* Step 4 - Day 4: Sitting on the edge of the bed
* Step 5 - Day 5: Sitting in a chair, standing up
* Step 6 - Day 6: Walking with or without assistance
* Step 7 - Day 7: Walking with or without assistance from today

Intervention Type BEHAVIORAL

Standard care

During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 ys
* Premorbid modified Rankin Scale score of 0-2
* WFNS I-IV at enrollment
* Aneurysm occlusion has occurred through open or endovascular means
* Minimum 24 hours elapsed after aneurysm occlusion
* The patient has not received thrombolytic therapy
* Vital parameters are appropriate (mean arterial pressure \[MAP\] \>80 or \>110 mm Hg)
* Signed patient information and consent form
* Enrollment occurs within 72 hours following ictus

Exclusion Criteria

* Age under 18 years
* Traumatic subarachnoid hemorrhage
* Incapacitated or limited capacity for action before ictus
* Confirmed pregnancy
* Aneurysm multiplicity (unless all aneurysms are treated)
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental, Neurological and Neurosurgery

UNKNOWN

Sponsor Role collaborator

Borsod-Abaúj-Zemplén County Central Hospital and University Teaching Hospital

UNKNOWN

Sponsor Role collaborator

University of Pecs

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Péter Csécsei

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Csecsei, MD. PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pecs

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Pecs

Pécs, Baranya, Hungary

Site Status RECRUITING

Central Hospital of B.A.Z. County

Miskolc, BAZ, Hungary

Site Status RECRUITING

National Institute of Mental Health, Neurology, and Neurosurgery

Budapest, , Hungary

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Hungary

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peter Csecsei, MD. PhD

Role: CONTACT

+0672535900

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Peter Csecsei, MD. PhD

Role: primary

Csaba Olah, MD. PhD

Role: primary

Sandor Nardai, MD. PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HunSAHEMob

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.